Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

St. Louis
13:16

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Cardio-Oncology Update: What Is the Long Term Efficacy of DRZ as a Cardioprotectant Among Childhood Cancer Survivors? Is There a Negative Impact of DRZ on Cancer Outcomes?

FEATURING Daniel Lenihan
  • 3 views
  • February 12, 2021
19:13

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Cardio-Oncology: How Does It Impact Treatment Choices and Outcomes? What Are the Prosper Study Results?

FEATURING Daniel Lenihan
  • 3 views
  • February 12, 2021
06:49

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on Locally Advanced Oropharynx Cancer: Can Surgery Enable Equivalent Efficacy With a Lower Dose of Adjuvant Radiation?

FEATURING Michael Gibson
  • 2 views
  • September 29, 2020
06:02

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HNSCC: Weekly vs. 3-Weekly Cisplatin - What Is the Appropriate/Cumulative Dose?

FEATURING Michael Gibson
  • 11 views
  • September 29, 2020
08:48

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Recurred/Metastatic ACC: Does Axitinib Increase PFS Rate Compared to Observation? How Does Tipifarnib Affect H&N Tumors With HRAS Mutations?

FEATURING Michael Gibson
  • 6 views
  • September 29, 2020
09:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Distant Caregivers and Use of Technology: What Are the Pros and Cons? What’s the Impact on the Patient Care?

FEATURING Jennifer Klemp
  • 1 view
  • September 17, 2020
10:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Cancer and Aging: How to Integrate Onco-Geriatric Care? What Tools Are Used and How Is the Clinical Practice Affected?

FEATURING Jennifer Klemp
  • 89 views
  • September 17, 2020
  • 2
14:51

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Genetic Testing: What Barriers Do We Need to Break Down? Review of MAGENTA & ProGen Trials

FEATURING Jennifer Klemp
  • 2 views
  • September 17, 2020
08:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ mCRC: Is Promising Trastuzumab Deruxtecan Active in Disease Refractory to Standard Therapies?

FEATURING Shikha Jain
  • 131 views
  • July 16, 2020
  • 1
06:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on BRAF V600E Mutant mCRC: Does FDA Approved Encorafenib + Cetuximab Significantly Improve OS, ORR, PFS relative vs. SOC?

FEATURING Shikha Jain
  • 372 views
  • July 14, 2020
  • 1
08:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Stage III CRC: Is There a Difference in 5 yr OS Between 3 vs. 6 Months of Adjuvant Therapy?

FEATURING Shikha Jain
  • 1,197 views
  • July 14, 2020
  • 4
06:48

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on CRC: Can We Consider Pembrolizumab a New First Line SoC in Patients With MSI-H mCRC?

FEATURING Shikha Jain
  • 552 views
  • July 14, 2020
  • 5
19:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Pancreatic Cancer Highlights: Is Perioperative mFOLFIRINOX More Beneficial Than Gem/nab-P in Resectable Disease? Should Neoadjuvant Therapy Be Considered for Borderline Resectable Disease?

FEATURING Heloisa Soares
  • 821 views
  • July 14, 2020
  • 5
11:51

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Esophageal / Gastric Cancers: Did Trastuzumab + Trimodality Treatment Increase DFS, PCR or OS of Esophageal Cancer? Is Pertuzumab / Trastuzumab + FLOT Showing Promising pCR?

FEATURING Heloisa Soares
  • 442 views
  • July 14, 2020
  • 3
05:29

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HCC: Donafenib vs. Sorafenib - Which Combination Is Beneficial as First-line Therapy in Advanced Disease?

FEATURING Heloisa Soares
  • 39 views
  • July 14, 2020
10:19

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on TILs in Advanced Melanoma: Does Lifileucel Improve OCR. & DCR in BRAFV600 Mutant Disease Progressed on Multiple Prior Therapies?

FEATURING Gary Doolittle
  • 74 views
  • July 22, 2020
08:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Metastatic Melanoma: What Is the Optimal Dosing of Ipilimumab + Nivolumab?

FEATURING Gary Doolittle
  • 174 views
  • July 22, 2020
  • 1
13:37

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on High-risk Resectable Stage III Melanoma: Can 2 Cycles of Neoadjuvant Ipi + Nivo Induce High pCR and Omit TLND to Reduce Surgical Morbidity?

FEATURING Gary Doolittle
  • 194 views
  • July 22, 2020
  • 1
05:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Follow up on Adjuvant Therapy in High-risk Melanoma: Does Pembro Provide Sustained RFS Benefit in Resected Stage III Melanoma? Is There a Long-term Survival Benefit With Dabrafenib + Trametinib in BRAF+ Disease?

FEATURING Gary Doolittle
  • 96 views
  • July 22, 2020
08:30

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Brentuximab Vedotin vs. Pembrolizumab - Which Single Agent Should You Pick First for R/R cHL?

FEATURING Neha Mehta-Shah
  • 390 views
  • July 22, 2020
  • 4
07:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Should You Abandon ASCT in Patients With PR Combination Chemotherapy in DLBCL?

FEATURING Neha Mehta-Shah
  • 277 views
  • July 22, 2020
  • 1
08:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update: Zanubrutinib vs. Ibrutinib - Are Newer Generation BTK Inhibitors Better for Waldenstrom’s Macroglobulinemia? Can Venetoclax Be Added to DA-R-EPOCH in DLBCL and Richter’s?

FEATURING Neha Mehta-Shah
  • 17 views
  • July 22, 2020
04:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Is Anti-CD47 Antibody Magrolimab + Azacitidine Effective and Well Tolerated in TP53-mutant AML?

FEATURING Ravi Vij
  • 15 views
  • July 22, 2020
07:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Are Ivosidenib and Enasidenib Good Options to Be Added to the Backbone of HMAs?

FEATURING Ravi Vij
  • 107 views
  • July 22, 2020
  • 1
19:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newly Diagnosed Disease, Weekly Selinexor Combo vs. Vd After Prior Therapy, Safety and Tolerability of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R Disease

FEATURING Ravi Vij
  • 336 views
  • July 22, 2020
  • 2
14:29

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recurrent Ovarian Cancer: Who Should Have a Secondary Cytoreduction?

FEATURING Sarah Temkin
  • 51 views
  • July 16, 2020
15:50

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on PARPi in Ovarian Cancer: Is BRCA Related to Therapeutic Value of PARPi? What Is the Ideal Therapy Timing?

FEATURING Sarah Temkin
  • 75 views
  • July 16, 2020
08:11

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update: What Is the Long-term Oncological Safety of SNL Biopsy in Early-stage Cervical Cancer? Which New pMMR Endometrial Cancer Options Are Under Investigation?

FEATURING Sarah Temkin
  • 16 views
  • July 16, 2020
16:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ EBC: Can We De-escalate Adjuvant Chemotherapy Using MammaPrint? What Is the Outcome of Fulvestrant +/- AI vs. AI? Can the new Breast Cancer Index Test Help Identify Patients Who May Benefit from Extended AI Therapy?

FEATURING Cynthia Ma
  • 468 views
  • July 16, 2020
  • 4
10:45

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ EBC: Is T-DM1 + Pertuzumab Superior in IDFS? Does Anthracycline Add Benefit to TaxolCarboHP Regimen? Is Early PET Response Predicting Higher PCR Rate a Good Strategy for De-escalation?

FEATURING Cynthia Ma
  • 120 views
  • July 13, 2020
05:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Early TNBC: Does Metronomic Capecitabine Improve DFS Following Standard Adjuvant Therapy?

FEATURING Cynthia Ma
  • 280 views
  • July 13, 2020
  • 2
11:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on ER+ MBC: Fulvestrant vs. Letrozole + Palbociclib in the First-line Setting - Is There an Optimal Endocrine Backbone for CDK4/6? Can Genomic Alterations Help Predict Responsiveness?

FEATURING Jane Meisel
  • 350 views
  • July 16, 2020
  • 2
09:18

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ MBC: Is Tucatinib the First TKI to Demonstrate Prolongation of OS in Patients With Brain Mets?

FEATURING Jane Meisel
  • 127 views
  • July 13, 2020
  • 1
11:47

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Metastatic TNBC: Are Chemoimmunotherapy Pembro Combinations Helpful in PD-L1+ Disease? Can TMB Help in Patient Selection? What Is the Role of PARPi Beyond BRCA?

FEATURING Jane Meisel
  • 191 views
  • July 13, 2020
  • 1
05:09

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on MBC: Is There a Survival Benefit for Surgery?

FEATURING Jane Meisel
  • 577 views
  • July 13, 2020
  • 2
14:57

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Curative Setting BC: Who Should Be Considered for Preoperative Systemic Therapy for EBC? Do We Always/Ever Need Anthracyclines? Can We Shorten Trastuzumab Duration?

FEATURING Reshma L. Mahtani
  • 377 views
  • July 13, 2020
  • 2
15:12

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Curative Setting BC: Pertuzumab to SoC Trastuzumab vs. Utilizing T-DM1 for Pts w/ Residual Disease vs. Extending Adjuvant Tx With 1 yr of Neratinib?

FEATURING Reshma L. Mahtani
  • 322 views
  • July 16, 2020
  • 2
17:22

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2 Targeted Therapy in HER2+ MBC: Efficacy Comparison of Sequencing Newly Approved T-DM1 vs. Neratinib vs. Tucatinib With Existing Therapies

FEATURING Reshma L. Mahtani
  • 334 views
  • July 13, 2020
  • 3
09:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: Does Extended Follow-up Continue to Support Pembrolizumab + Axitinib as a SoC for Patients With Previously Untreated Disease?

FEATURING Russell Pachynski
  • 37 views
  • July 15, 2020
10:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: Does Nivolumab Monotherapy Represent an Alternative Frontline Approach in Treatment-naive Patients?

FEATURING Russell Pachynski
  • 85 views
  • July 15, 2020
10:41

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced mUC: Is There a DFS Benefit to Adjuvant CPI in MIUC?

FEATURING Russell Pachynski
  • 19 views
  • July 15, 2020
06:35

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mUC: Can We Consider Recently FDA Approved Avelumab Maintenance a New 1st-line SoC? Is Switch Maintenance Checkpoint Inhibition Preferred Over a Treatment Break Followed by 2nd Line?

FEATURING Russell Pachynski
  • 47 views
  • July 15, 2020
14:06

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on SCLC: Anti-PD-1/L1 Staple for 1st L Treatment (Atezolizumab and Durvalumab + EP Improve OS, Pembro Improve PFS) & Safety, Tolerability and Efficacy of Liposomal Irinotecan in 2nd L Setting

FEATURING Jason Porter
  • 136 views
  • July 13, 2020
12:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Metastatic NSCLC w/o Actionable Mutations: Chemo-Free Option With Nivo + Ipi, Nivo + Ipi + Chemo Safe and Tolerable & Data on Novel Anti-TIGIT Agent Tiragolumab + Atezo

FEATURING Jason Porter
  • 292 views
  • July 15, 2020
  • 1
09:53

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapies for NSCLC: Clinical Activity of T-Dxd in HER2 Mutated NSCLC & Feasibility of Osimertinib/Gefitinib Combination in EGFR-mutated Disease

FEATURING Jason Porter
  • 278 views
  • July 13, 2020
  • 2